Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has announced that it will receive $4.6 million from Alnylam Pharmaceuticals as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company and Alnylam.
Subscribe to our email newsletter
In addition, Isis has the potential to receive portions of future milestone and royalty payments. According to the company, this transaction further emphasizes the value of Isis’s innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics.
In 2004, Isis and Alnylam entered into a strategic relationship in which Alnylam obtained an exclusive license to Isis’s intellectual property for double-stranded oligonucleotide therapeutics that mediate RNAi. In return, Isis received an upfront payment and financial participation in future transactions supported by Isis’ patents.
Stan Crooke, chairman and CEO of Isis Pharmaceuticals, said: “Isis has benefited substantially from Alnylam’s business development and financial successes. We look forward to additional successes from this valuable strategic relationship.”